PriceTargets.com logo

Morphic - MORF Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $61.00
  • Forecasted Upside: 109.12%
  • Number of Analysts: 6
  • Breakdown:
  • 0 Sell Ratings
  • 2 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$29.17 As of 04/23/2024 03:27 PM ET
▲ +0.67 (2.35%)

This chart shows the closing price for MORF by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Morphic Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for MORF and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for MORF

Analyst Price Target is $61.00
▲ +109.12% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for Morphic in the last 3 months. The average price target is $61.00, with a high forecast of $80.00 and a low forecast of $33.00. The average price target represents a 109.12% upside from the last price of $29.17.

This chart shows the closing price for MORF for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 6 contributing investment analysts is to moderate buy stock in Morphic. This Moderate Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
10/31/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
1/29/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
4/29/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
7/28/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
10/26/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
1/24/2024
  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
3/24/2024
  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
4/23/2024

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
12/8/2023CitigroupInitiated CoverageBuy$46.00Low
10/16/2023Leerink PartnrsReiterated RatingOutperformLow
9/28/2023BMO Capital MarketsLower TargetOutperform ➝ Outperform$106.00 ➝ $52.00Low
9/25/2023Stifel NicolausLower TargetHold ➝ Hold$61.00 ➝ $33.00Low
9/25/2023BTIG ResearchDowngradeBuy ➝ NeutralLow
8/8/2023Stifel NicolausDowngradeBuy ➝ Hold$69.00 ➝ $61.00Low
7/21/2023Berenberg BankInitiated CoverageBuy$75.00Low
4/26/2023BMO Capital MarketsBoost Target$83.00 ➝ $106.00Low
4/26/2023Royal Bank of CanadaBoost Target$75.00 ➝ $80.00Low
4/25/2023Wells Fargo & CompanyBoost Target$67.00 ➝ $80.00Low
3/8/2023SVB LeerinkBoost TargetOutperform$45.00 ➝ $56.00Low
3/8/2023SVB SecuritiesBoost Target$45.00 ➝ $56.00Low
11/8/2022Wells Fargo & CompanyBoost TargetOverweight$77.00 ➝ $78.00Low
11/3/2022Royal Bank of CanadaBoost TargetOutperform$70.00 ➝ $75.00Low
9/6/2022Stifel NicolausInitiated CoverageBuy$44.00Low
8/5/2022BMO Capital MarketsReiterated RatingBuy$83.00Low
8/4/2022Wells Fargo & CompanyLower TargetOverweight$79.00 ➝ $77.00Low
8/4/2022Royal Bank of CanadaLower TargetOutperform$76.00 ➝ $70.00N/A
7/20/2022SVB LeerinkInitiated CoverageOutperform$45.00Low
3/31/2022Canaccord Genuity GroupInitiated CoverageBuyLow
2/28/2022BMO Capital MarketsLower Target$102.00 ➝ $83.00High
2/25/2022Royal Bank of CanadaLower TargetOutperform$82.00 ➝ $76.00Medium
2/11/2022BTIG ResearchInitiated CoverageBuy$64.00High
12/8/2021Wells Fargo & CompanyInitiated CoverageOverweight$81.00High
5/3/2021BMO Capital MarketsLower TargetOutperform$111.00 ➝ $102.00High
3/1/2021Wells Fargo & CompanyBoost Target$40.00 ➝ $103.00High
2/2/2021Royal Bank of CanadaBoost TargetOutperform$35.00 ➝ $50.00Low
10/26/2020Royal Bank of CanadaInitiated CoverageOutperform$35.00High
8/26/2020BMO Capital MarketsReiterated RatingBuy$37.00Medium
8/11/2020BMO Capital MarketsBoost TargetOutperform$30.00 ➝ $37.00Low
7/5/2020BMO Capital MarketsReiterated RatingBuyLow
3/5/2020CowenReiterated RatingBuyLow
8/13/2019BMO Capital MarketsBoost TargetOutperform$30.00 ➝ $32.00High
8/12/2019CowenReiterated RatingBuyHigh
7/22/2019Jefferies Financial GroupInitiated CoverageBuy ➝ BuyHigh
7/22/2019CowenInitiated CoverageOutperform ➝ OutperformHigh
7/22/2019Wells Fargo & CompanyInitiated CoverageOutperform ➝ OutperformHigh
7/22/2019BMO Capital MarketsInitiated CoverageOutperform ➝ Outperform$30.00High
(Data available from 4/23/2019 forward)

News Sentiment Rating

0.78 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 4 very positive mentions
  • 6 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
Mentions as of
9/26/2023
  • 1 very positive mentions
  • 8 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
Mentions as of
10/26/2023
  • 4 very positive mentions
  • 8 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
11/25/2023
  • 2 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/25/2023
  • 2 very positive mentions
  • 2 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
1/24/2024
  • 10 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/23/2024
  • 9 very positive mentions
  • 12 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/24/2024
  • 2 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/23/2024

Current Sentiment

  • 2 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Morphic logo
Morphic Holding, Inc., a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, and metabolic diseases, as well as fibrosis and cancer. Its lead product candidate MORF-057, an a4ß7-specific integrin inhibitor affecting inflammation is in Phase 2 clinical trials for the treatment of inflammatory bowel disease. The company's products in pipeline include Next Gen a4ß7 Inhibitors for additional potential GI indications, such as EGIDs, pouchitis, etc.; avß8 for the treatment of Myelofibrosis and solid tumor; and fibronectin integrin for pulmonary hypertensive. In addition, it has a license agreement with Janssen to discover and develop novel integrin therapeutics; collaboration agreement with Schrödinger for integrin targets; and license agreement with Children's Medical Center Corporation to develop and commercialize products worldwide for any therapeutic or diagnostic use in humans and veterinary applications. Morphic Holding, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.
Read More

Today's Range

Now: $29.17
Low: $28.25
High: $29.31

50 Day Range

MA: $33.91
Low: $27.51
High: $39.53

52 Week Range

Now: $29.17
Low: $19.34
High: $63.08

Volume

302,405 shs

Average Volume

500,842 shs

Market Capitalization

$1.46 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.42

Frequently Asked Questions

What sell-side analysts currently cover shares of Morphic?

The following equities research analysts have issued research reports on Morphic in the last twelve months: Berenberg Bank, BMO Capital Markets, BTIG Research, Citigroup Inc., Leerink Partnrs, Royal Bank of Canada, Stifel Nicolaus, TheStreet, and Wells Fargo & Company.
View the latest analyst ratings for MORF.

What is the current price target for Morphic?

6 Wall Street analysts have set twelve-month price targets for Morphic in the last year. Their average twelve-month price target is $61.00, suggesting a possible upside of 109.1%. Wells Fargo & Company has the highest price target set, predicting MORF will reach $80.00 in the next twelve months. Stifel Nicolaus has the lowest price target set, forecasting a price of $33.00 for Morphic in the next year.
View the latest price targets for MORF.

What is the current consensus analyst rating for Morphic?

Morphic currently has 2 hold ratings and 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for MORF.

What other companies compete with Morphic?

Other companies that are similar to Morphic include ANI Pharmaceuticals, Ligand Pharmaceuticals, Kura Oncology, Gyre Therapeutics and Zai Lab. Learn More about companies similar to Morphic.

How do I contact Morphic's investor relations team?

Morphic's physical mailing address is 35 Gatehouse Drive A2, Waltham MA, 02451. The company's listed phone number is (781) 996-0955. The official website for Morphic is www.morphictx.com. Learn More about contacing Morphic investor relations.